

CORRECTION

Open Access



Correction: Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* and chloroquine and dihydroartemisinin-piperaquine for uncomplicated *Plasmodium vivax* infection in Ethiopia

Ashenaf Assefa^{1,2*}, Hussein Mohammed¹, Anjoli Anand^{3,4}, Adugna Abera¹, Heven Sime¹, Anna A. Minta^{3,4}, Mekonnen Tadesse⁵, Yehualashet Tadesse⁵, Samuel Girma^{5,6}, Worku Bekele⁷, Kebede Etana⁸, Bereket Hailegiorgis Alemayehu⁵, Hiwot Teka⁶, Dereje Dilu⁸, Mebrahtom Haile⁸, Hiwot Solomon⁸, Leah F. Moriarty⁹, Zhiyong Zhou⁴, Samaly Souza Svigel⁴, Bryan Ezema⁴, Geremew Tasew¹, Adugna Woyessa¹, Jimée Hwang⁹ and Matthew Murphy⁹

Correction: *Malaria Journal* (2022) 21:359
<https://doi.org/10.1186/s12936-022-04350-z>

Following publication of the original article [1], the authors flagged that they had erroneously reported (in Table 4 + the subsection 'Resistance markers') an S1034N mutation in the *Pfmdr1* gene. In addition (in the subsection 'Resistance markers'), they erroneously reported a total of 50 samples in place of a total of 50 Day 0 samples.

The original article has been updated to correct these errors. The authors thank you for reading and apologize for any inconvenience caused.

Published online: 11 April 2023

The original article can be found online at <https://doi.org/10.1186/s12936-022-04350-z>.

*Correspondence:

Ashenaf Assefa
ashyaega@yahoo.com

¹ Ethiopian Public Health Institute, Addis Ababa, Ethiopia

² Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

³ Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA

⁴ Malaria Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA

⁵ ICAP at Columbia University, Addis Ababa, Ethiopia

⁶ U.S. President's Malaria Initiative, USA Agency for International Development, Addis Ababa, Ethiopia

⁷ World Health Organization, Addis Ababa, Ethiopia

⁸ Ethiopian Federal Ministry of Health, Addis Ababa, Ethiopia

⁹ U.S. President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, GA, USA



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reference

1. Assefa A, Mohammed H, Anand A, Abera A, Sime H, Minta AA, Tadesse M, Tadesse Y, Girma S, Bekele W, Etana K, Alemayehu BH, Teka H, Dilu D, Haile M, Solomon H, Moriarty LF, Zhou Z, Svigel SS, Ezema B, Tasew G, Woyessa A, Hwang J, Murphy M. Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated *Plasmodium falciparum* and chloroquine and dihydroartemisinin-piperaquine for uncomplicated *Plasmodium vivax* infection in Ethiopia. *Malar J*. 2022;21:359. <https://doi.org/10.1186/s12936-022-04350-z>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.